Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.

Cancer control : journal of the Moffitt Cancer Center - 1 Jan 2000

Rizzo Alessandro, Federico Alessandro Di, Ricci Angela Dalia, Frega Giorgio, Palloni Andrea, Pagani Rachele, Tavolari Simona, Marco Mariacristina Di, Brandi Giovanni

Abstract excerpt

BACKGROUND: Biliary tract cancers (BTCs) represent a heterogeneous group of aggressive solid tumors with limited therapeutic options, and include gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA). METHODS & RESULTS: In the current review, we will discuss recent results of clinical trials testing targeted therapies in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Ducts
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Gallbladder

Share to Molecular Targeted Therapy

Share to Observational Studies as Topic

Share to Progression-Free Survival

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 33356500
DOI: 10.1177/1073274820983013
PMCID: PMC8642057

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.PMID 33356500Read ↗

Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.Semantic proximity Read ↗

Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports.Semantic proximity Read ↗

Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Semantic proximity Read ↗

Translating cancer genomics for precision oncology in biliary tract cancers.Semantic proximity Read ↗

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment OptionsSemantic proximity Read ↗

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsSemantic proximity Read ↗

Systemic treatment options for advanced biliary tract carcinoma.Semantic proximity Read ↗

Emerging molecular target antagonists for the treatment of biliary tract cancer.Semantic proximity Read ↗

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving ParadigmSemantic proximity Read ↗

The Epidemiology of Biliary Tract Cancer and Associated Prevalence of MDM2 Amplification: A Targeted Literature ReviewSemantic proximity Read ↗

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.